FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969263485> ?p ?o ?g. }

• W2969263485 endingPage "3882" @default.
• W2969263485 startingPage "3882" @default.
• W2969263485 abstract "Abstract Unprecedented achievement has been made in the treatment of childhood ALL within the past decades. However, how to improve the outcome of Ph+ALL remains a conundrum for the care providers towards the cure of the disease. Using Auto-hematopoietic stem cell transplant (HSCT), after a negative BCR-ABL, or allo-HSCT has become the curative options for Ph+ALL cases although either relapse or life threatening transplant related complications could lead to treatment failure. To determine the safety and efficiency of a dasatinib based mild induction with homobarringtonie, cytarabine, G-SCF (HAG) contained regimen, we enrolled 67 patients with de novo Ph+ALL from 2012-2017 for the trial. The medium follow-up time was 39 months (17 months to 65 months). In brief, the induction consisted of vincristine and prednisone, in addition to daily dasatinib (70mg; bid), followed by six cycles of HAG regimen (homobarringtonie 1mg/m2/days 1-14; G-CSF 5ug/kg on day one; Ara-C 10mg/q12h/days 1-14; every three month/cycle) plus daily dasatinib (70mg; bid). The maintenance included two cycles of HAG (every six months) in addition to daily dasatinib. The intrathecal injection was given 11 times along with the treatment to prevent CNS leukemia. A serial MRD detection of BCR-ABL by qPCR was performed every three months. There were four patients eligible for the study. Among the 63 evaluated patients, 55 (88%) achieved CR in induction. There was no treatment related mortality during the induction. Good prednisone response was indicated among 51 patients (81%) on day eight. The day 30 MRD detection for those in CR indicated 43 (68%) reached ≤5 *10-2 and four (7%) achieved 10-3. The MRD detection at month three and six suggested that 38 (60%) vs 33 (52%) patients were within the level of ≤5 *10-2 and six (10%) vs 10 (16%) achieved 10-3, respectively. Relapse-related death occurred in 11 of 63 patients (16%), and four patients (6%) experienced treatment-related mortality. Grade 3-4 adverse events were observed among 10 cases (30%). The main toxicities were liver dysfunction and coagulation abnormality which can be solved by close monitoring and multi-disciplinary care. Four-year probability of event-free survival (pEFS) was found to be 58%. Those who went with hematopoietic stem cell transplantation (HSCT) after chemotherapy achieved significantly better pEFS than only chemotherapy (65.7% vs 50.5%,p=0.03). Our protocol can be used as an effective and less toxic treatment option to improve the outcome of Ph+ALL with promising survival and acceptable adverse effects shedding new light on treating Ph+ALL. Disclosures No relevant conflicts of interest to declare." @default.
• W2969263485 created "2019-08-29" @default.
• W2969263485 creator A5086042023 @default.
• W2969263485 date "2017-12-07" @default.
• W2969263485 modified "2023-09-28" @default.
• W2969263485 title "Treatment Outcome of Dasatinib in Combination with Less-Intensive Induction, Homobarringtonie, Cytarabine, G-SCF in Newly Diagnosed Patients with Ph+ALL" @default.
• W2969263485 doi "https://doi.org/10.1182/blood.v130.suppl_1.3882.3882" @default.
• W2969263485 hasPublicationYear "2017" @default.
• W2969263485 type Work @default.
• W2969263485 sameAs 2969263485 @default.
• W2969263485 citedByCount "0" @default.
• W2969263485 crossrefType "journal-article" @default.
• W2969263485 hasAuthorship W2969263485A5086042023 @default.
• W2969263485 hasConcept C126322002 @default.
• W2969263485 hasConcept C141071460 @default.
• W2969263485 hasConcept C2776694085 @default.
• W2969263485 hasConcept C2776755627 @default.
• W2969263485 hasConcept C2777583451 @default.
• W2969263485 hasConcept C2778041864 @default.
• W2969263485 hasConcept C2778283404 @default.
• W2969263485 hasConcept C2778461978 @default.
• W2969263485 hasConcept C2778720950 @default.
• W2969263485 hasConcept C2778729363 @default.
• W2969263485 hasConcept C2778822529 @default.
• W2969263485 hasConcept C2779429289 @default.
• W2969263485 hasConcept C2779536868 @default.
• W2969263485 hasConcept C2781413609 @default.
• W2969263485 hasConcept C71924100 @default.
• W2969263485 hasConcept C90924648 @default.
• W2969263485 hasConceptScore W2969263485C126322002 @default.
• W2969263485 hasConceptScore W2969263485C141071460 @default.
• W2969263485 hasConceptScore W2969263485C2776694085 @default.
• W2969263485 hasConceptScore W2969263485C2776755627 @default.
• W2969263485 hasConceptScore W2969263485C2777583451 @default.
• W2969263485 hasConceptScore W2969263485C2778041864 @default.
• W2969263485 hasConceptScore W2969263485C2778283404 @default.
• W2969263485 hasConceptScore W2969263485C2778461978 @default.
• W2969263485 hasConceptScore W2969263485C2778720950 @default.
• W2969263485 hasConceptScore W2969263485C2778729363 @default.
• W2969263485 hasConceptScore W2969263485C2778822529 @default.
• W2969263485 hasConceptScore W2969263485C2779429289 @default.
• W2969263485 hasConceptScore W2969263485C2779536868 @default.
• W2969263485 hasConceptScore W2969263485C2781413609 @default.
• W2969263485 hasConceptScore W2969263485C71924100 @default.
• W2969263485 hasConceptScore W2969263485C90924648 @default.
• W2969263485 hasLocation W29692634851 @default.
• W2969263485 hasOpenAccess W2969263485 @default.
• W2969263485 hasPrimaryLocation W29692634851 @default.
• W2969263485 hasRelatedWork W1625508716 @default.
• W2969263485 hasRelatedWork W1940304947 @default.
• W2969263485 hasRelatedWork W2185333728 @default.
• W2969263485 hasRelatedWork W2284341874 @default.
• W2969263485 hasRelatedWork W2421677385 @default.
• W2969263485 hasRelatedWork W2463334306 @default.
• W2969263485 hasRelatedWork W2534381827 @default.
• W2969263485 hasRelatedWork W2545351978 @default.
• W2969263485 hasRelatedWork W2551361778 @default.
• W2969263485 hasRelatedWork W2553243483 @default.
• W2969263485 hasRelatedWork W2553513956 @default.
• W2969263485 hasRelatedWork W2557440595 @default.
• W2969263485 hasRelatedWork W2559231919 @default.
• W2969263485 hasRelatedWork W2561291203 @default.
• W2969263485 hasRelatedWork W2563620804 @default.
• W2969263485 hasRelatedWork W2565002467 @default.
• W2969263485 hasRelatedWork W2566756057 @default.
• W2969263485 hasRelatedWork W2587386273 @default.
• W2969263485 hasRelatedWork W2592553025 @default.
• W2969263485 hasRelatedWork W2613704621 @default.
• W2969263485 hasVolume "130" @default.
• W2969263485 isParatext "false" @default.
• W2969263485 isRetracted "false" @default.
• W2969263485 magId "2969263485" @default.
• W2969263485 workType "article" @default.